Mylan Critic Blumenthal Asks FDA to Help End EpiPen Shortage
- Connecticut Democrat says he’s alarmed by injector supply woes
- Patients are having difficulty getting the allergy device
A Mylan NV EpiPen.
Photographer: Daniel Acker/Bloomberg
This article is for subscribers only.
U.S. Senator Richard Blumenthal, who criticized Mylan NV for jacking up the price of its EpiPen allergy shot two years ago, called on federal officials to help end what he called an urgent and alarming shortage of the life-saving device.
In a letter to Food and Drug Administration Commissioner Scott Gottlieb on Monday, the Connecticut Democrat said the agency should work closely with manufacturers and distributors to eliminate shortages of EpiPen and other epinephrine auto-injectors. The FDA said May 9 that while the EpiPen was still available, delays at Pfizer Inc.’s Meridian Medical Technologies, which manufactures the device for Mylan, had led to “intermittent supply constraints.”